Mixed set of numbers in Q4 – strong top-line but profitability behind the street’s expectations, with the ageing (hence depleting) drugs weighing on the newer ones. The bigger concern, which is likely to keep investors’ confidence muted, is the weak guidance for 2019 and an extended investment period, which would require the company to cut the dividend from 60-80% earlier to 30-60% from 2019. The strategic review also aims at increasing the focus on buying growth from outsid
06 Feb 2019
Mixed Q4, weak guidance, dividend cut...not so rosy
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mixed Q4, weak guidance, dividend cut...not so rosy
Mixed set of numbers in Q4 – strong top-line but profitability behind the street’s expectations, with the ageing (hence depleting) drugs weighing on the newer ones. The bigger concern, which is likely to keep investors’ confidence muted, is the weak guidance for 2019 and an extended investment period, which would require the company to cut the dividend from 60-80% earlier to 30-60% from 2019. The strategic review also aims at increasing the focus on buying growth from outsid